A new Health Insurance Portability and Accountability Act (HIPAA) privacy rule went into effect on June 25, that prohibits the disclosure of protected health information related to lawful reproductive health care in certain situations. Employers, as covered entities under HIPAA, must comply with the rule by Dec. 23.
Under the previous HIPAA privacy regulations, healthcare providers were allowed, but not required, to share patients’ reproductive health information with law enforcement. Such information could include contraception use, pregnancy- related care—including miscarriage and abortion—as well as infertility treatment.
The Biden administration issued the new rule after hearing concerns from providers that patients’ records could be unlawfully sought when they travel out of state to obtain reproductive care, especially after the Supreme Court overturned Roe v. Wade in June 2022. Several states instituted abortion restrictions and bans following the decision, causing some patients to cross state lines for care.
What the New Rule Covers
The new HIPAA reproductive health privacy rule aims to better protect patient confidentiality and prevent medical records from being used against those legally obtaining or providing reproductive care.
However, the rule does not:
- Cover reproductive health information when the services obtained were illegal
- Cover data outside of HIPAA protections, like location information or health details stored on personal devices
- Apply unless the care was lawfully obtained in a state where it is legal.
Required Signed Attestations
Under the new regulations, if a HIPAA-covered entity like an employer receives a request for protected health information potentially involving reproductive care, they must get a signed attestation stating the data will not be utilized for prohibited reasons.
Valid attestations must be provided on a standalone form, not attached to other documents when disclosing information for:
- Health oversight activities
- Judicial and administrative proceedings
- Law enforcement purposes
- Releases to coroners and medical examiners.
The Office for Civil Rights plans to publish a model attestation form to aid compliance ahead of the Dec. 23 deadline.
For more Employee Benefits resources, contact INSURICA today.
Copyright © 2024 Smarts Publishing. This is not intended to be exhaustive nor should any discussion or opinions be construed as legal advice. Readers should contact legal counsel or an insurance professional for appropriate advice.
About the Author
Share This Story
Related Blogs
Fiduciary Responsibilities for Employer Health Plans: What Employers Should Know Now
When employers think about fiduciary responsibility, retirement plans often come to mind first. But recent developments make it clear that fiduciary duties also matter—sometimes significantly—when it comes to employer-sponsored health and welfare plans.
The New Era of Mental Health Parity Enforcement in 2026
Federal agencies have made mental health parity enforcement a top priority in 2026, and employers sponsoring group health plans are feeling the impact. Regulators are no longer satisfied with high‑level assurances that plans comply with the Mental Health Parity and Addiction Equity Act (MHPAEA). Instead, they expect detailed, data‑driven documentation showing that mental health and substance‑use‑disorder benefits are truly comparable to medical and surgical benefits. This includes not only the written plan design but also how rules are applied in real‑world scenarios.
The 2026 Specialty Drug Surge: What Employers Need to Prepare For
Specialty drugs have been a major cost driver for years, but 2026 marks a significant shift in both scale and urgency. With GLP 1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more than 60% of total pharmacy spending this year. That’s a dramatic change for employers, especially considering that specialty drugs represent fewer than 5% of total prescriptions.